Methixene

Summary

Methixene (CHEMBL1201342) is an approved small-molecule antiparkinson drug (ATC N04AA03); indicated across 1 condition including parkinson disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N04AA03
• Indications: 1 condition
• Chemistry: 309.5 Da · C20H23NS

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201342
Name	Methixene
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4167
ChEBI	CHEBI:51024
ATC	N04AA03
Molecular formula	C20H23NS
Molecular weight	309.5
InChIKey	MJFJKKXQDNNUJF-UHFFFAOYSA-N

SMILES: CN1CCCC(C1)CC2C3=CC=CC=C3SC4=CC=CC=C24

IUPAC name: 1-methyl-3-(9H-thioxanthen-9-ylmethyl)piperidine

Pharmacological roles (ChEBI): antiparkinson drug, muscarinic antagonist, histamine antagonist.

Also known as: Atosil, Metixene, Metixeno, methixene, METHIXENE, metixene, METIXENE

Parent form; salt/anhydrous children: CHEMBL1200426, CHEMBL2359044

Patent coverage: 419 distinct patent families (1,320 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,272 (96%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 14 (assay-derived). Sample: Alpha-2A adrenergic receptor, D(1A) dopamine receptor, Thromboxane A2 receptor, Muscarinic acetylcholine receptor M2, 5-hydroxytryptamine receptor 1A, Muscarinic acetylcholine receptor M1, Sodium-dependent noradrenaline transporter, Sodium-dependent serotonin transporter, Alpha-1A adrenergic receptor, Mu-type opioid receptor.

Bioactivity

ChEMBL activities: 11 potent at pChembl ≥ 5 of 15 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CHRM2	8.28	AC50	5.3	nM	CHEMBL_ACT_25196392
CHRM2	8.27	AC50	5.4	nM	CHEMBL_ACT_25196017
CHRM1	7.96	AC50	10.9	nM	CHEMBL_ACT_25210448
ADRA1A	6.23	AC50	586.1	nM	CHEMBL_ACT_25219088
DRD3	6.13	AC50	741.6	nM	CHEMBL_ACT_25194795
P81908	5.8	IC50	1600	nM	CHEMBL_ACT_6217892
HTR1A	5.72	AC50	1901	nM	CHEMBL_ACT_25165305
DRD1	5.69	AC50	2032	nM	CHEMBL_ACT_25115491
KCNH2	5.51	AC50	3100	nM	CHEMBL_ACT_25118173
SLC6A2	5.48	AC50	3289	nM	CHEMBL_ACT_25146281
ADRA2A	5.32	AC50	4817	nM	CHEMBL_ACT_25156710

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Parkinson disease	4	MONDO:0005180	MONDO:0005180

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).